Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.746 USD | +1.76% | -5.48% | -1.76% |
Financials (USD)
Sales 2024 * | 5.59M | Sales 2025 * | 3.67M | Capitalization | 40.08M |
---|---|---|---|---|---|
Net income 2024 * | -63M | Net income 2025 * | -66M | EV / Sales 2024 * | 5.31 x |
Net cash position 2024 * | 10.4M | Net Debt 2025 * | 29.1M | EV / Sales 2025 * | 18.9 x |
P/E ratio 2024 * |
-0.67
x | P/E ratio 2025 * |
-0.72
x | Employees | 55 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.57% |
Latest transcript on Cara Therapeutics, Inc.
1 day | +1.76% | ||
1 week | -5.48% | ||
Current month | -2.93% | ||
1 month | -12.27% | ||
3 months | +29.00% | ||
6 months | -34.24% | ||
Current year | -1.76% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 54 | 18-08-05 | |
Ryan Maynard
DFI | Director of Finance/CFO | 54 | 22-09-11 |
Scott Terrillion
CMP | Compliance Officer | 61 | 16-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Martin Vogelbaum
CHM | Chairman | 60 | 10-06-30 |
Jeffrey Ives
BRD | Director/Board Member | 73 | 14-07-15 |
Helen Boudreau
BRD | Director/Board Member | 58 | 23-08-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
11.20% | 0 M€ | +26.93% | - | |
1.29% | 13 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-09 | 0.7298 | -0.44% | 5 527 |
24-05-08 | 0.7331 | -7.46% | 259,732 |
24-05-07 | 0.7922 | +0.28% | 183,296 |
24-05-06 | 0.79 | +1.52% | 355,263 |
24-05-03 | 0.7782 | +0.78% | 159,125 |
Delayed Quote Nasdaq, May 09, 2024 at 09:59 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.76% | 40.08M | |
-3.35% | 88.91B | |
+4.08% | 41.25B | |
-14.81% | 31.99B | |
+49.81% | 24.73B | |
-15.26% | 15.54B | |
-40.39% | 12.07B | |
-8.63% | 12.05B | |
-14.37% | 12.02B | |
+6.22% | 8.84B |
- Stock Market
- Equities
- CARA Stock